Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.66 |
| ▸ | PDE6D | O43924 | 2/20 | 0.51 |
| ▸ | PDE6A | P16499 | 2/20 | 0.51 |
| ▸ | PDE6G | P18545 | 2/20 | 0.51 |
| ▸ | PDE6B | P35913 | 2/20 | 0.51 |
| ▸ | PDE6C | P51160 | 2/20 | 0.51 |
| ▸ | PDE6H | Q13956 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5595917 | 0.85 | PDE5A (0.71) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7168952 | 0.84 | PDE5A (0.70) | PDE5A | |
| SCHEMBL7166649 | 0.83 | PDE5A (0.81) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL4997159 | 0.80 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL5595830 | 0.78 | PDE5A (0.75) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7165733 | 0.74 | PDE5A (0.91) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL7163507 | 0.70 | PDE5A (0.85) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6702289 | 0.70 | PDE5A (0.88) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL6698101 | 0.70 | PDE5A (0.84) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL19197657 | 0.70 | PDE5A (0.57) | PDE5APDE6DPDE6APDE6GPDE6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173042-B2 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | claimed |
| US-20050113358-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BI YINGZHI (US) | 2005-05-26 | — | — | US | claimed |
| US-20030225128-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BI YINGZHI (US) | 2003-12-04 | — | — | US | claimed |
| US-20020177587-A1 | Quinoline inhibitors of cGMP phosphodiesterase | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113358-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6D 19/4885PDE6A 8/4885 |
| US-20030225128-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6D 24/4885PDE6A 6/4885 |
| US-20020177587-A1 | Quinoline inhibitors of cGMP phosphodiesterase | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6D 27/4885PDE6A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.